Insurance

Wegovy prior authorization: criteria, checklist, and approval

Wegovy is FDA-approved for weight management, so if your plan covers weight-loss drugs, approval usually comes down to documented criteria — and Wegovy is often the preferred agent. Below: the exact requirements, a documentation checklist, the renewal rule that catches people at month four, and the cardiovascular path most people miss.

Written byGLP1Zoom Editorial, Medical content team · Independent editorial

Medically reviewed byGLP1Zoom Editorial Team, Evidence-based editorial review Reviewed Jun 10, 2026

Verified Jul 2026 · re-checked quarterlyBy the GLP1Zoom editorial teamWe compare, we don’t sell

The short answer

Typical Wegovy PA criteria: BMI ≥30, or ≥27 with a weight-related condition; a documented ~90-day lifestyle program; and, to renew, ≥5% weight loss from baseline. Wegovy is often a preferred weight-loss agent (so no step therapy). If you have heart disease, the cardiovascular-risk indication is a separate path that can win coverage even where weight-loss drugs are excluded.

Key takeaways

Wegovy PA: BMI ≥30, or ≥27 with a weight-related comorbidity — documented in your chart.
A supervised diet-and-exercise program is usually required (often ~90 days, with dates and content).
Renewal typically requires ≥5% weight loss from baseline at ~4-6 months — record your starting weight or the renewal fails.
Wegovy is a preferred weight-loss agent on many plans (often no step therapy), and a Wegovy trial can be the step required before Zepbound.
Separate path: Wegovy's FDA cardiovascular-risk indication (March 2024) may open coverage on plans — and Medicare — that exclude weight-loss drugs.
A flat weight-loss benefit exclusion is NOT a PA problem — pivot to the CV indication, the Medicare Bridge, or cash-pay (~$349/mo, $199 intro).

What your plan typically requires

Requirement	What satisfies it
BMI ≥30, or ≥27 + a condition	Chart-documented BMI; if 27–30, a diagnosed comorbidity (hypertension, T2D, dyslipidemia, OSA, or CVD)
Documented lifestyle program	Records of a supervised diet-and-exercise attempt, commonly ~90 days — dates and content, not an attestation
Baseline weight	Recorded at initiation — this is the number your ≥5% renewal is measured against
Step therapy (sometimes)	Usually not required for Wegovy (often preferred); if required, document the prior trial and outcome
Renewal: ≥5% loss	Documented weight loss ≥5% from baseline at re-authorization (~4–6 months)

Why Wegovy is often the easier approval

Several major PBMs — CVS Caremark among them — designate Wegovy as the preferred weight-loss GLP-1. Practically, that means two things: you usually don't have to fail another drug before getting Wegovy, and if you later want Zepbound, a documented Wegovy trial (often 12–16 weeks with less than 5% loss, or intolerance) may be the step your plan requires first. If your goal is the fastest approval on a plan that covers weight-loss drugs, Wegovy is frequently the path of least resistance.

The cardiovascular path (most people miss this)

Since March 2024, Wegovy is FDA-approved to reduce the risk of heart attack, stroke, and cardiovascular deathin adults with established cardiovascular disease plus overweight/obesity. That's a non-weight-loss indication — so plans that exclude weight-loss drugs, and Medicare(which excludes them by law), may still cover Wegovy for cardiovascular risk reduction when it's documented. If you have established heart disease, have your prescriber pursue that indication explicitly. See GLP-1s and heart health and Medicare coverage.

The renewal rule: don't lose coverage at month four

Approval isn't permanent. At re-authorization (commonly 4–6 months in), most plans require documented ≥5% weight loss from baselineto continue covering Wegovy — mirroring the FDA label's reassessment guidance. Renewals most often fail because the baseline weight was never recorded, or weights were captured inconsistently. Confirm the baseline is in your chart on day one, and ask for weight to be recorded the same way each visit.

Denied? Match the fix to the reason

Denial reason	Fix
Missing documentation	Submit baseline weight, lifestyle-program records, comorbidity diagnosis; resubmit
BMI criteria not met	Document a qualifying comorbidity if BMI is 27–30
Step therapy required	Document the required trial and outcome, or intolerance
Non-preferred / non-formulary	Request a formulary exception (medical necessity)
Weight-loss drugs excluded	Pivot: CV-risk indication, Medicare Bridge, or cash-pay

Steps and deadlines: denial appeal · formulary exception · the cross-drug PA pillar · plan-by-plan detail in Wegovy insurance coverage.

These are typical criteria as of 2026-07 and vary by plan — many employer plans exclude weight-loss GLP-1s entirely, and PBM policies revise quarterly. Confirm your specific plan's policy. Educational only, not medical or insurance advice.

Providers who handle Wegovy prior authorization

Common questions about Wegovy prior authorization

What are the prior authorization criteria for Wegovy?

The common commercial criteria are: a BMI of 30 or higher, or 27 or higher with a weight-related condition (high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, or heart disease); documentation of a supervised diet-and-exercise program (often about 90 days); and, to renew coverage, documented weight loss of at least 5% from your starting weight. Because Wegovy is FDA-approved for weight management, many plans that cover weight-loss drugs make it a preferred option. Your specific plan's rules can differ.

Does Wegovy require step therapy?

Often not for Wegovy itself. Several major pharmacy benefit managers (including CVS Caremark) make Wegovy a preferred weight-loss agent, meaning you may not have to try another drug first — and in some plans, a Wegovy trial is actually the step required before they approve Zepbound. That said, some plans do require an oral weight-loss agent or another step first, so check your plan's policy before assuming.

What documentation do I need for Wegovy approval?

Your chart should have: current height, weight, and BMI; if your BMI is 27–30, a documented qualifying comorbidity; records of a supervised diet-and-exercise program (commonly ~90 days, with dates); and your baseline weight recorded at initiation — that baseline is what your ≥5% renewal will be measured against. If your plan requires step therapy, add documentation of the prior trial and its outcome.

How do I get Wegovy approved by insurance?

Make sure your chart documents your BMI and, if it is 27–30, a qualifying comorbidity; document a supervised lifestyle program; and record your baseline weight. Then have your prescriber submit a complete prior authorization. If your plan covers weight-loss drugs, meeting these criteria usually gets Wegovy approved — it is frequently the preferred agent. If denied, identify the exact reason, request a peer-to-peer review, and appeal or request a formulary exception as appropriate.

Can Wegovy be covered for heart-disease risk instead of weight loss?

Yes — and this is the most underused path. Wegovy also has an FDA-approved indication (since March 2024) to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease and overweight/obesity. Because that is a non-weight-loss indication, some plans — and Medicare, which excludes weight-loss drugs by law — may cover Wegovy for cardiovascular risk reduction when it is documented. If you have established heart disease, ask your prescriber to pursue that indication explicitly.

What happens at Wegovy renewal — can coverage be taken away?

Yes, if you don't meet the continuation rule. Most plans require documented weight loss of at least 5% from baseline at re-authorization (commonly 4–6 months in) to keep covering Wegovy — mirroring the FDA label's own reassessment guidance. The two most common reasons renewals fail are a missing baseline weight (nothing to measure against) and inconsistently recorded weights. Confirm the baseline is in your chart at the start, and have weight recorded the same way at each visit.

What if my plan doesn't cover weight-loss drugs at all?

Then meeting the PA criteria won't help — a flat benefit exclusion isn't a criteria question. Your options: pursue the cardiovascular-risk indication if you have established heart disease; check the Medicare GLP-1 Bridge ($50/month) if you're on Medicare; or use cash-pay — Wegovy self-pay runs about $349/month (with a $199 introductory price), and the federal TrumpRx portal lists the pen from about $199 and the pill from about $149.

Sources

Criteria reflect typical commercial PBM policies (UnitedHealthcare, OptumRx) and the FDA Wegovy label (indications + continuation rules); the cardiovascular indication from the FDA March 2024 approval. Exact thresholds vary by plan. Reviewed 2026-07-18. Educational only.

References(4)

Our sourcing standards →

Wegovy (semaglutide 2.4 mg) Prescribing Information — indications (weight management + CV risk), continuation criteriaNIH — US FDA label via DailyMed (2026)
UnitedHealthcare — Weight Loss (GLP-1) Prior Authorization criteria (BMI, lifestyle, >5% reauth) — UnitedHealthcare (commercial) (2026)
OptumRx — GLP-1 Receptor Agonists Prior Authorization guidelines — OptumRx (PBM medical policy) (2026)
FDA approves first treatment to reduce cardiovascular risk in adults with obesity or overweight (Wegovy, Mar 2024)FDA — US FDA (2024)